🔗 Share this article

Given that the US proceeds with unprecedented adjustments to its vaccination schedules, an unexpected name appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by questioning COVID-19 vaccinations during the global health crisis and has concentrated on potential fatalities following COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Immunization Schedule

Health officials planned to unveil major changes to the pediatric vaccine schedule in December, synchronizing the US with the Danish vaccine program, sources say – a substantial departure that would place the US out of step with a large portion of the global community with insufficient data for improved outcomes. This reveal has been pushed back until the new year.

Rather than the director of the vaccine center, Høeg is scheduled to present at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to run the office this year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Høeg has often pushed for ending specific childhood vaccine recommendations in the US to become more like Denmark's approach, a nation with universal health coverage and a population approximately the population of the state of Wisconsin.

In her initial public appearances, she has kept her attention on immunizations – usually the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Doubts Over Background

Høeg has little discernible background in drug development, oversight or leadership, which has been customary for previous leaders of the biologics center. She has been employed at the FDA as a top consultant to the agency head and CBER since spring.

“She appears not to have the necessary background” for running the CDER, remarked Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a major agency. She is not an expert in industry regulation.”

Former directors of CBER would “understand legal statutes and the research of drug development”, commented Janet Woodcock. “Objectively, she has not acquired the sort of resume that former directors who led the center have had.”

This division has an vast workload at the agency, Woodcock pointed out.

“Everybody just pays attention on the innovative therapies, but the off-patent medication office authorizes numerous generic medications. There’s a biosimilars division, non-prescription drug unit and other areas, and all of those need to be supervised,” Woodcock said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a substantial leadership element to the role, which manages in excess of 5,000 personnel. “It is a enormous leadership role, if you perform it correctly,” she concluded.

Agency Reaction and Contentious Programs

When asked about concerns about Dr. Høeg's credentials and whether this assignment signifies more teamwork among FDA leaders on immunizations, a press secretary said that the “questions stem from inaccurate assumptions”.

“This background matches the duties of her role,” the official stated, noting the time Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a contentious expedited therapy clearance system that reportedly concerned her preceding directors. “How are these medications being chosen for this fast-track system? Who takes the calls?” Howard asked. “There’s a lot of secrecy occurring at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration appears to be shifting towards less stringent rules of all drugs, aside from immunizations.”

Documented Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if concerning, past, some experts observe. She published a study using unverified crowd-sourced reports to estimate the incidence of heart inflammation following Covid vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the incoming administration featured altering guidelines for recently developed shots and halting “non-essential” immunizations, she said following the vote on a online show. At the agency, Høeg has allegedly suggested barring young men from receiving Covid vaccinations.

“She is an thorough ideologue who begins with her conclusions and tailors the evidence to retrofit the science in a highly deceptive, dishonest way,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with other dissenters, {like|